Evidence of ABL-kinase domain mutations in highly purified primitive stem cell populations of patients with chronic myelogenous leukemia.

Sorel, N

Evidence of ABL-kinase domain mutations in highly purified primitive stem cell populations of patients with chronic myelogenous leukemia. [electronic resource] - Biochemical and biophysical research communications Oct 2004 - 728-30 p. digital

Publication Type: Comparative Study; Evaluation Study; Journal Article

0006-291X

10.1016/j.bbrc.2004.08.169 doi


Antineoplastic Agents--administration & dosage
Benzamides
Cell Differentiation--drug effects
Cells, Cultured
Drug Resistance--genetics
Enzyme Inhibitors--administration & dosage
Fusion Proteins, bcr-abl--genetics
Gene Expression Regulation, Neoplastic--drug effects
Genetic Predisposition to Disease--genetics
Genetic Testing--methods
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy
Mutation
Phosphotransferases--antagonists & inhibitors
Piperazines--administration & dosage
Protein Structure, Tertiary
Pyrimidines--administration & dosage
Sequence Analysis, Protein
Stem Cells--drug effects
Structure-Activity Relationship
Tumor Cells, Cultured